ATLANTA, Sept. 11,
2024 /PRNewswire/ -- Kedrion Biopharma Inc. is
excited to announce its sponsorship of the National Bleeding
Disorders Foundation's (NBDF) 76th Annual Bleeding Disorders
Conference (BDC) in Atlanta,
Georgia. The event will take place from September 12-14, 2024, and will bring together
individuals with bleeding disorders, their families, healthcare
professionals, and researchers from across the country.
Kedrion's sponsorship of the NBDF underscores the company's
commitment to supporting the bleeding disorders community. Kedrion
is a leading manufacturer of coagulation and rare disease therapies
and is dedicated to providing patients with access to innovative
treatments.
The NBDF Conference is a unique opportunity for attendees to
learn about the latest advancements in bleeding and clotting
disorders research and treatment, connect with other individuals
and families affected by these conditions, and gain valuable
insights from experts in the field. The conference will feature a
wide range of educational sessions, workshops, and networking
opportunities, covering topics such as:
- Treatment options and advancements: Attendees will have
the chance to learn about the latest developments in treatment
options for various bleeding and clotting disorders, including new
therapies and clinical trials.
- Living with a bleeding and or clotting disorder: The
conference will address the challenges and opportunities associated
with living with a diagnosis, including managing symptoms,
navigating healthcare systems, and building support networks.
- Research and advocacy: Attendees will gain insights into
ongoing research efforts and advocacy initiatives aimed at
improving the lives of individuals with such disorders.
Kedrion will be actively involved in the NBDF Conference,
hosting several events and activities designed to engage with
attendees and share information about its therapies. Highlights
will be a Campfire presentation on the results of the Hereditary
Factor X in Americas survey, the 2nd Annual Plasminogen
Deficiency Roundtable and The Ultra Rare Networking Hour, a
dedicated space for individuals with ultra-rare bleeding and or
clotting disorders and their support network to connect and build
relationships. This initiative will foster a sense of community and
provide a platform for sharing experiences and resources.
The NBDF Conference is also a valuable opportunity for Kedrion
to connect with individuals living with Plasminogen Deficiency Type
1(PLGD-1), as well as patients with Hereditary Factor X Deficiency
(HFXD), two rare and potentially life-threatening disorders. The
company will be sharing information about the therapy developments
in these areas and its ongoing research efforts.
"At Kedrion, every employee is united by a powerful mission: to
amplify the voices of patients with rare diseases and to
continually improve their journey and care. Together, our global
commitment ensures that every step forward is a step towards a
brighter, more hopeful future" said Bob
Rossilli, CCO, Global Business and US General Manager of
Kedrion.
Kedrion's participation in the NBDC reflects the company's
commitment to improving the lives of individuals with rare
diseases. By providing support, education, and access to innovative
therapies, Kedrion is working to ensure that patients have the
resources they need to live full and healthy lives.
To learn more about the NBDF's 76th Annual Bleeding Disorders
Conference, please visit National Bleeding Disorders Foundation,
formerly NHF | NBDF.
Contact: Jennifer
Bayliss / j.bayliss@kedrion.com /
213-703-9604
View original content to download
multimedia:https://www.prnewswire.com/news-releases/kedrion-biopharmas-focus-on-advancing-patient-care-in-rare-disease-to-be-showcased-at-nbdf-conference-2024-302245958.html
SOURCE Kedrion Biopharma